Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Peter Wessman"'
Publikováno v:
ESC Heart Failure, Vol 9, Iss 4, Pp 2464-2473 (2022)
Abstract Aim Patients with advanced heart failure (HF) frequently suffer from renal insufficiency. The impact of durable mechanical circulatory support (MCS) and subsequent heart transplantation (HTx) on kidney function is not well described. Methods
Externí odkaz:
https://doaj.org/article/029c03b829454d7c877f107406f74db3
Autor:
Mona Bafadhel, Dave Singh, Christine Jenkins, Stefan Peterson, Thomas Bengtsson, Peter Wessman, Malin Fagerås
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-10 (2020)
Abstract Background Clinically Important Deterioration (CID) is a novel composite measure to assess treatment effect in chronic obstructive pulmonary disease (COPD). We examined the performance and utility of CID in assessing the effect of inhaled co
Externí odkaz:
https://doaj.org/article/fb9709e22f4446eb9d72fff30ed2d662
Autor:
Mattis Gottlow, David J. Svensson, Ilya Lipkovich, Monika Huhn, Karin Bowen, Peter Wessman, Gene Colice
Publikováno v:
BMC Pulmonary Medicine, Vol 19, Iss 1, Pp 1-17 (2019)
Abstract Background Tralokinumab is an anti–interleukin (IL)-13 monoclonal antibody investigated for the treatment of severe, uncontrolled asthma in two Phase III clinical trials, STRATOS 1 and 2. The STRATOS 1 biomarker analysis plan was developed
Externí odkaz:
https://doaj.org/article/f4f21a2a11e644edb914a6951c01018d
Autor:
Meghan M. Moran, Peter Wessman, Ola Rolfson, Daniel D. Bohl, Johan Kärrholm, Ali Keshavarzian, D. Rick Sumner
Publikováno v:
PLoS ONE, Vol 16, Iss 11 (2021)
Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the intestinal tract and is associated with decreased bone mineral density. IBD patients are at higher risk of osteopenia, osteoporosis and fracture compared to non-IBD pati
Externí odkaz:
https://doaj.org/article/d52c83a94c5946ffb0c604989c987f40
Autor:
Andrew Menzies-Gow, Jonathan Corren, Elisabeth H. Bel, Jorge Maspero, Liam G. Heaney, Mark Gurnell, Peter Wessman, Ubaldo J. Martin, Shahid Siddiqui, Esther Garcia Gil
Publikováno v:
ERJ Open Research, Vol 5, Iss 3 (2019)
Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal antibody approved in several countries for the add-on maintenance treatment of patients with severe eosinophilic asthma aged 12 years and older. In the 28-week Phase III ZONDA
Externí odkaz:
https://doaj.org/article/d1cc32954de64ee6ba2b41d24fa14da6
Autor:
Peter Wessman, Gene L. Colice, Mattis Gottlow, Ilya Lipkovich, Karin Bowen, David Svensson, Monika Huhn
Publikováno v:
BMC Pulmonary Medicine, Vol 19, Iss 1, Pp 1-17 (2019)
BMC Pulmonary Medicine
BMC Pulmonary Medicine
Background Tralokinumab is an anti–interleukin (IL)-13 monoclonal antibody investigated for the treatment of severe, uncontrolled asthma in two Phase III clinical trials, STRATOS 1 and 2. The STRATOS 1 biomarker analysis plan was developed to ident
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3abfdc6f5d86e3a3900f9cfbe140212b
http://link.springer.com/article/10.1186/s12890-019-0889-4
http://link.springer.com/article/10.1186/s12890-019-0889-4
Autor:
Johan Kärrholm, Ola Rolfson, Peter Wessman, D. Rick Sumner, Daniel D. Bohl, Ali Keshavarzian, Meghan M. Moran
Publikováno v:
PLoS ONE, Vol 16, Iss 11, p e0257310 (2021)
PLoS ONE
PLoS ONE, Vol 16, Iss 11 (2021)
PLoS ONE
PLoS ONE, Vol 16, Iss 11 (2021)
Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the intestinal tract and is associated with decreased bone mineral density. IBD patients are at higher risk of osteopenia, osteoporosis and fracture compared to non-IBD pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80082c0c039fec6ce9ec559cf7f2333d
https://doaj.org/article/506335bee9344c78a3cdabf4578a409a
https://doaj.org/article/506335bee9344c78a3cdabf4578a409a
Autor:
Thomas Bengtsson, Peter Wessman, Dave Singh, Christine Jenkins, Malin Fagerås, Stefan Peterson, Mona Bafadhel
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-10 (2020)
Respiratory Research
Respiratory research, 21:17
Respiratory Research
Respiratory research, 21:17
Background Clinically Important Deterioration (CID) is a novel composite measure to assess treatment effect in chronic obstructive pulmonary disease (COPD). We examined the performance and utility of CID in assessing the effect of inhaled corticoster
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c957cd605559be8ff646f229c0c57488
https://doi.org/10.1186/s12931-020-1280-y
https://doi.org/10.1186/s12931-020-1280-y
Autor:
Edward Piper, KKarin Bowen, Christopher E. Brightling, AnnaMaria Péterffy, Gene L. Colice, Reynold A. Panettieri, Ulf Sjöbring, Peter Wessman
Publikováno v:
The Lancet Respiratory Medicine. 6:511-525
Summary Background Tralokinumab is an anti-interleukin-13 human monoclonal antibody developed for the treatment of severe, uncontrolled asthma. These clinical trials aimed to assess the efficacy and safety of tralokinumab in this population. Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb88e405b546ef80b5e2dd1e9bf248dc
https://doi.org/10.1016/s2213-2600(18)30184-x
https://doi.org/10.1016/s2213-2600(18)30184-x
Autor:
Liam G Heaney, Shahid Siddiqui, E. Garcia Gil, Jonathan Corren, Ubaldo J. Martin, Andrew Menzies-Gow, Mark Gurnell, Jorge Maspero, Peter Wessman, Elisabeth H. Bel
Publikováno v:
A32. ASTHMA: CLINICAL STUDIES II.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::375917da5723ce11909ba0a3dba4b2d1
https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a1320
https://doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a1320